{"url_path":"/sec/gri/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1824293/0001824293-26-000044-index.html","accession_number":"0001824293-26-000044","cik":"0001824293","ticker":"GRI","issuer_name":"GRI Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1824293/0001824293-26-000044-index.html","primary_entity_key":"0001824293","primary_entity_name":"GRI Bio, Inc."},"word_count":49,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\nRule 10b5-1 Trading Arrangements\n\nDuring the three months ended March 31, 2026, none of our directors or officers adopted or terminated “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.\n\n25\n\n[Table of Contents](#i50f83595bfc24cd3be8c8dbcbb826d3e_7)"}